Sydney-based OncoSil (ASX:OSL) has announced another senior appointment.
The company is developing and commercialising OncoSil, a localised radiation therapy treatment with the potential benefit of reducing the risk of serious side effects often associated with standard radiotherapy.
The company recently announced the appointment of Mr David James as its Global Head of Manufacturing Operations, and Dr Greg Rogers as Manufacturing Engineering Manager.
The company also recently announced that Fast Track review by the European regulator to assess its CE Mark application for OncoSil in pancreatic and primary liver cancer has been completed. It is now awaiting the final outcome of the review as the Notified Body continues its assessment over the coming weeks.
"The Company was pleased with the review meeting and anticipates that the Notified Body will make a decision in respect of the CE Mark for OncoSil in November," it said.
Now the company has announced the appointment of Tom Milicevic as its Chief Financial Officer and Company Secretary.
Mr Milicevic is an experienced commercial, financial and management accountant with more than two decades experience in a career that includes a number of major Australian and international companies.
Prior to joining OncoSil, Mr Milicevic was CEO and CFO of orthopaedic medical device company Allegra Orthopaedics and led the company through its IPO and listing on the ASX.
His previous roles include CFO and Company Secretary with ASX listed oncology-focussed biotech company Avantogen Limited, before its relocation to the US, and senior finance and accounting roles with Cochlear, Boral and Smorgon Steel.